Our FibroScan family of products
FibroScan is a pain-free, non-invasive examination of the liver, providing physicians with both liver stiffness and liver fat scores in a single 10-minute procedure. Our FibroScan family of products all come equipped to offer you the same capabilities and examination experience, allowing you the flexibility to choose the size and portability options that suit your needs best.
Unprecedented Mobility for Liver Assessment Efficiency
The FibroScan mini+ is our most portable system, weighing in just over 10lbs, our mini+ is the smallest addition to the FibroScan family of products for access to those who need it most.
Learn more
Innovation in Liver Disease Management
With its optional roll stand, big 15” touchscreen display, durable yet ergonomic design, the FibroScan Compact is a perfect liver assessment solution for any point-of-care setting.
Learn more
FDA Cleared
FibroScan is the first and only point of care device specifically developed and FDA-Cleared as an aid to the diagnosis and monitoring of adult patients with liver disease. The Shear wave speed stiffness generated by the FibroScan examination may be used as an aid to clinical management of pediatric patients with liver disease.
Learn more about FDA clearance
Deployed at Beth Israel
"FibroScan is the most effective and best screening test for the diagnosis of chronic liver disease"
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center
See how FibroScan is helping BIDMC
Current media
Rise of Liver Cancer Rates and Link to Non-alcoholic Fatty Liver Disease Highlight Importance of Early Detection
Join us in supporting October 2020 Liver Cancer Awareness Month In the spirit of Liver Cancer Awareness Month this October, Echosens would like to highlight some alarming trends to help…
Read More
FibroScan and Chronic Care Liver Disease Management
Self-Insured Employers Can Boost Workforce Productivity, Reduce Medical Costs Download our latest white paper: “Comprehensive Chronic Care Disease Management of Liver Disease Improves Member Outcomes, Reduces Costs for Employer-…
Read More
Economic Analysis Model Suggests Screening People for Fibrosis With Non-Invasive Tests Cost-effective
NASH Network (NASHNET), a global network of thought leaders dedicated to advancing care pathways for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), has published a novel cost-effectiveness analysis…
Read More
Contact a representative
In North America there are over 1200+ FibroScan systems in operation & we’re growing!
Speak to a Representative
